202 related articles for article (PubMed ID: 37310433)
1. Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents.
Battin C; De Sousa Linhares A; Leitner J; Grossmann A; Lupinek D; Izadi S; Castilho A; Waidhofer-Söllner P; Grabmeier-Pfistershammer K; Stritzker J; Steinberger P
Cancer Immunol Immunother; 2023 Sep; 72(9):3029-3043. PubMed ID: 37310433
[TBL] [Abstract][Full Text] [Related]
2. 4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.
Cannons JL; Lau P; Ghumman B; DeBenedette MA; Yagita H; Okumura K; Watts TH
J Immunol; 2001 Aug; 167(3):1313-24. PubMed ID: 11466348
[TBL] [Abstract][Full Text] [Related]
3. 4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.
Wen T; Bukczynski J; Watts TH
J Immunol; 2002 May; 168(10):4897-906. PubMed ID: 11994439
[TBL] [Abstract][Full Text] [Related]
4. Dispensable role for 4-1BB and 4-1BBL in development of vaccinia virus-specific CD8 T cells.
Zhao Y; Croft M
Immunol Lett; 2012 Jan; 141(2):220-6. PubMed ID: 22037570
[TBL] [Abstract][Full Text] [Related]
5. Expression of 4-1BB and 4-1BBL in thymocytes during thymus regeneration.
Kim YM; Kim HK; Kim HJ; Lee HW; Ju SA; Choi BK; Kwon BS; Kim BS; Kim JB; Lim YT; Yoon S
Exp Mol Med; 2009 Dec; 41(12):896-911. PubMed ID: 19745604
[TBL] [Abstract][Full Text] [Related]
6. A novel form of 4-1BBL has better immunomodulatory activity than an agonistic anti-4-1BB Ab without Ab-associated severe toxicity.
Schabowsky RH; Elpek KG; Madireddi S; Sharma RK; Yolcu ES; Bandura-Morgan L; Miller R; MacLeod KJ; Mittler RS; Shirwan H
Vaccine; 2009 Dec; 28(2):512-22. PubMed ID: 19836479
[TBL] [Abstract][Full Text] [Related]
7. The systemic administration of Ig-4-1BB ligand in combination with IL-12 gene transfer eradicates hepatic colon carcinoma.
Xu DP; Sauter BV; Huang TG; Meseck M; Woo SL; Chen SH
Gene Ther; 2005 Oct; 12(20):1526-33. PubMed ID: 15973445
[TBL] [Abstract][Full Text] [Related]
8. CD28-independent, TRAF2-dependent costimulation of resting T cells by 4-1BB ligand.
Saoulli K; Lee SY; Cannons JL; Yeh WC; Santana A; Goldstein MD; Bangia N; DeBenedette MA; Mak TW; Choi Y; Watts TH
J Exp Med; 1998 Jun; 187(11):1849-62. PubMed ID: 9607925
[TBL] [Abstract][Full Text] [Related]
9. 4-1BB ligand activates bystander dendritic cells to enhance immunization in trans.
Macdonald DC; Hotblack A; Akbar S; Britton G; Collins MK; Rosenberg WC
J Immunol; 2014 Nov; 193(10):5056-64. PubMed ID: 25305314
[TBL] [Abstract][Full Text] [Related]
10. A switch in costimulation from CD28 to 4-1BB during primary versus secondary CD8 T cell response to influenza in vivo.
Bertram EM; Dawicki W; Sedgmen B; Bramson JL; Lynch DH; Watts TH
J Immunol; 2004 Jan; 172(2):981-8. PubMed ID: 14707071
[TBL] [Abstract][Full Text] [Related]
11. Constitutive interaction between 4-1BB and 4-1BBL on murine LPS-activated bone marrow dendritic cells masks detection of 4-1BBL by TKS-1 but not 19H3 antibody.
Mbanwi AN; Lin GHY; Wang KC; Watts TH
J Immunol Methods; 2017 Nov; 450():81-89. PubMed ID: 28789924
[TBL] [Abstract][Full Text] [Related]
12. Crystal structure of murine 4-1BB and its interaction with 4-1BBL support a role for galectin-9 in 4-1BB signaling.
Bitra A; Doukov T; Wang J; Picarda G; Benedict CA; Croft M; Zajonc DM
J Biol Chem; 2018 Jan; 293(4):1317-1329. PubMed ID: 29242193
[TBL] [Abstract][Full Text] [Related]
13. A Novel Form of 4-1BBL Prevents Cancer Development via Nonspecific Activation of CD4
Barsoumian HB; Batra L; Shrestha P; Bowen WS; Zhao H; Egilmez NK; Gomez-Gutierrez JG; Yolcu ES; Shirwan H
Cancer Res; 2019 Feb; 79(4):783-794. PubMed ID: 30770367
[TBL] [Abstract][Full Text] [Related]
14. Expression and function of 4-1BB and 4-1BB ligand on murine dendritic cells.
Futagawa T; Akiba H; Kodama T; Takeda K; Hosoda Y; Yagita H; Okumura K
Int Immunol; 2002 Mar; 14(3):275-86. PubMed ID: 11867564
[TBL] [Abstract][Full Text] [Related]
15. A novel agonist of 4-1BB costimulatory receptor shows therapeutic efficacy against a tobacco carcinogen-induced lung cancer.
Gulen AE; Rudraboina R; Tarique M; Ulker V; Shirwan H; Yolcu ES
Cancer Immunol Immunother; 2023 Nov; 72(11):3567-3579. PubMed ID: 37605009
[TBL] [Abstract][Full Text] [Related]
16. Production of recombinant human trimeric CD137L (4-1BBL). Cross-linking is essential to its T cell co-stimulation activity.
Rabu C; Quéméner A; Jacques Y; Echasserieau K; Vusio P; Lang F
J Biol Chem; 2005 Dec; 280(50):41472-81. PubMed ID: 16204238
[TBL] [Abstract][Full Text] [Related]
17. Crystal structure of the human 4-1BB/4-1BBL complex.
Gilbreth RN; Oganesyan VY; Amdouni H; Novarra S; Grinberg L; Barnes A; Baca M
J Biol Chem; 2018 Jun; 293(25):9880-9891. PubMed ID: 29720399
[TBL] [Abstract][Full Text] [Related]
18. 4-1BB and OX40 act independently to facilitate robust CD8 and CD4 recall responses.
Dawicki W; Bertram EM; Sharpe AH; Watts TH
J Immunol; 2004 Nov; 173(10):5944-51. PubMed ID: 15528328
[TBL] [Abstract][Full Text] [Related]
19. IL-15-dependent induction of 4-1BB promotes antigen-independent CD8 memory T cell survival.
Pulle G; Vidric M; Watts TH
J Immunol; 2006 Mar; 176(5):2739-48. PubMed ID: 16493029
[TBL] [Abstract][Full Text] [Related]
20. SA-4-1BBL costimulation inhibits conversion of conventional CD4+ T cells into CD4+ FoxP3+ T regulatory cells by production of IFN-γ.
Madireddi S; Schabowsky RH; Srivastava AK; Sharma RK; Yolcu ES; Shirwan H
PLoS One; 2012; 7(8):e42459. PubMed ID: 22870329
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
